A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide alone in newly diagnosed Elderly patients with Glioblastoma (NUTMEG) to analyse overall survival.
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Nivolumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms NUTMEG
- 17 Apr 2018 Status changed from not yet recruiting to recruiting.
- 18 Dec 2017 Planned initiation date changed from 1 Aug 2018 to 15 Jan 2018.
- 23 Feb 2017 New trial record